EP220/#471 High expression of phosphodiesterase 1 (PDE1A) promotes poor prognosis and associated with platinum based chemotherapy resistance in epithelial ovarian cancer. (4th December 2022)
- Record Type:
- Journal Article
- Title:
- EP220/#471 High expression of phosphodiesterase 1 (PDE1A) promotes poor prognosis and associated with platinum based chemotherapy resistance in epithelial ovarian cancer. (4th December 2022)
- Main Title:
- EP220/#471 High expression of phosphodiesterase 1 (PDE1A) promotes poor prognosis and associated with platinum based chemotherapy resistance in epithelial ovarian cancer
- Authors:
- Han, Gwan Hee
Yun, Hee
Kim, Hyosun
Chung, Joon-Yong
Kim, Sunghoon
Kim, Jae-Hoon
Cho, Hanbyoul - Abstract:
- Abstract : Objectives: Phosphodiesterase 1A (PDE1A) belongs to phosphohydrolytic enzymes resulting integration of Ca2+ and cyclic nucleotide mediate signaling in various cancers. However, its role in epithelial ovarian cancer (EOC) has not been clarified yet. Therefore, in this study we aim to evaluate the functional role and clinicopathological significance of PDE1A in EOC Methods: Expression level of PDE1A was screened by RNA sequencing of EOCs and normal ovarian epithelial tissues, GEO dataset and immunohistochemitry of EOCs. Associations of clinicopathological features and prognosis with PDE1A in EOC patients were analyzed and the its functional roles were evaluated in EOC cell lines. Results: Significantly overexpression of PDE1A was observed in EOCs compared to borderline, benign and normal nonadjacent ovarian epithelial tissues by IHC. Also, overexpression of PDE1A was significantly associated with serous, high grade, and advanced FIGO stage. Importantly, overexpression of PDE1A was associated poor overall survival and disease free survival compared with low expression of PDE1A in EOCs, and was associated with platinum based chemotherapy resistance. In vitro results demonstrated the knockdown of PDE1A was significantly associated with decreased cell invasion, migration, proliferation, and colony forming abilities supporting the oncogenic role in EOC. Also, FACS annexin V double staining assay revealed significant increased apoptosis in PDE1A knockdown EOC cell lines.Abstract : Objectives: Phosphodiesterase 1A (PDE1A) belongs to phosphohydrolytic enzymes resulting integration of Ca2+ and cyclic nucleotide mediate signaling in various cancers. However, its role in epithelial ovarian cancer (EOC) has not been clarified yet. Therefore, in this study we aim to evaluate the functional role and clinicopathological significance of PDE1A in EOC Methods: Expression level of PDE1A was screened by RNA sequencing of EOCs and normal ovarian epithelial tissues, GEO dataset and immunohistochemitry of EOCs. Associations of clinicopathological features and prognosis with PDE1A in EOC patients were analyzed and the its functional roles were evaluated in EOC cell lines. Results: Significantly overexpression of PDE1A was observed in EOCs compared to borderline, benign and normal nonadjacent ovarian epithelial tissues by IHC. Also, overexpression of PDE1A was significantly associated with serous, high grade, and advanced FIGO stage. Importantly, overexpression of PDE1A was associated poor overall survival and disease free survival compared with low expression of PDE1A in EOCs, and was associated with platinum based chemotherapy resistance. In vitro results demonstrated the knockdown of PDE1A was significantly associated with decreased cell invasion, migration, proliferation, and colony forming abilities supporting the oncogenic role in EOC. Also, FACS annexin V double staining assay revealed significant increased apoptosis in PDE1A knockdown EOC cell lines. Conclusions: Our study is the first work to identify an oncogenic role and association with chemotherapy resistance of PDE1A in EOC which may provide insights into the application of PDE1A as a novel predictive biomarker for prognosis and chemotherapy and a potential therapeutic target in EOC patients … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 3
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 3
- Issue Display:
- Volume 32, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 3
- Issue Sort Value:
- 2022-0032-0003-0000
- Page Start:
- A138
- Page End:
- A138
- Publication Date:
- 2022-12-04
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-igcs.311 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24966.xml